Seven Fleet Capital Management LP Sells 96,652 Shares of Silence Therapeutics PLC Sponsored ADR $SLN

Seven Fleet Capital Management LP trimmed its position in Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) by 61.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 60,107 shares of the company’s stock after selling 96,652 shares during the quarter. Seven Fleet Capital Management LP owned 0.13% of Silence Therapeutics worth $660,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in SLN. Boothbay Fund Management LLC increased its position in shares of Silence Therapeutics by 1.0% in the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock valued at $1,464,000 after acquiring an additional 2,409 shares during the period. Massar Capital Management LP purchased a new stake in shares of Silence Therapeutics during the second quarter worth about $115,000. UBS Group AG boosted its holdings in shares of Silence Therapeutics by 34.5% during the third quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after purchasing an additional 78,854 shares during the period. Two Sigma Investments LP grew its stake in shares of Silence Therapeutics by 6.6% in the third quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock worth $328,000 after purchasing an additional 3,935 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Silence Therapeutics in the third quarter worth about $112,000. Institutional investors own 98.73% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on SLN shares. Cantor Fitzgerald started coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating for the company. Morgan Stanley boosted their target price on Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Silence Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $53.50.

Silence Therapeutics Trading Down 1.4%

Shares of SLN stock opened at $14.59 on Friday. Silence Therapeutics PLC Sponsored ADR has a 12-month low of $4.19 and a 12-month high of $17.58. The stock has a market capitalization of $878.46 million, a P/E ratio of -11.40 and a beta of 1.45. The firm’s 50 day moving average is $12.06 and its 200 day moving average is $8.43.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. As a group, equities analysts predict that Silence Therapeutics PLC Sponsored ADR will post -1.03 earnings per share for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.